StockWatch
·
Biotechnology: Pharmaceutical Preparations
DelistingNov 20, 2026, 05:01 PM

60 Degrees Pharmaceuticals Faces Nasdaq Delisting; Plans Reverse Split

AI Summary

60 Degrees Pharmaceuticals, Inc. received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement due to the stock closing below $1.00 for 30 consecutive business days. The company has requested a hearing with the Nasdaq Hearings Panel and plans to effect a reverse stock split, expected to be effective December 2, 2026, to regain compliance. The company's securities will be scheduled for delisting unless the appeal is successful.

Key Highlights

  • 60 Degrees Pharmaceuticals received a Nasdaq delisting notice due to bid price closing below $1.00 for 30 consecutive days.
  • The company has requested a hearing with the Nasdaq Hearings Panel to appeal the delisting determination.
  • A reverse stock split is planned, expected to be effective December 2, 2026, to increase the bid price.
  • The company paid a $20,000 hearing fee, which stays the suspension of trading pending the Panel's decision.
  • Securities will be suspended from trading on December 1, 2026, if no appeal is requested by November 27, 2026.